Alnylam Pharmaceuticals Statistics
Share Statistics
Alnylam Pharmaceuticals has 130.39M
shares outstanding. The number of shares has increased by 2.83%
in one year.
| Shares Outstanding | 130.39M |
| Shares Change (YoY) | 2.83% |
| Shares Change (QoQ) | 0.85% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 8,622 |
| FTD / Avg. Volume | 0.84% |
Short Selling Information
The latest short interest is 3.68M, so 2.84% of the outstanding
shares have been sold short.
| Short Interest | 3.68M |
| Short % of Shares Out | 2.84% |
| Short % of Float | 3.76% |
| Short Ratio (days to cover) | 3.38 |
Valuation Ratios
The PE ratio is -107.99 and the forward
PE ratio is 163.5.
Alnylam Pharmaceuticals's PEG ratio is
2.79.
| PE Ratio | -107.99 |
| Forward PE | 163.5 |
| PS Ratio | 13.36 |
| Forward PS | 5.1 |
| PB Ratio | 447.73 |
| P/FCF Ratio | -705.29 |
| PEG Ratio | 2.79 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Alnylam Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.78,
with a Debt / Equity ratio of 19.32.
| Current Ratio | 2.78 |
| Quick Ratio | 2.71 |
| Debt / Equity | 19.32 |
| Debt / EBITDA | -7.25 |
| Debt / FCF | -30.43 |
| Interest Coverage | -1.25 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,008,180.72 |
| Profits Per Employee | $-124,734.08 |
| Employee Count | 2,230 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 4.12 |
Taxes
| Income Tax | -99.22M |
| Effective Tax Rate | 26.29% |
Stock Price Statistics
The stock price has increased by 102.78% in the
last 52 weeks. The beta is 0.17, so Alnylam Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.17 |
| 52-Week Price Change | 102.78% |
| 50-Day Moving Average | 264.15 |
| 200-Day Moving Average | 262.08 |
| Relative Strength Index (RSI) | 66.72 |
| Average Volume (20 Days) | 1,029,034 |
Income Statement
In the last 12 months, Alnylam Pharmaceuticals had revenue of 2.25B
and earned -278.16M
in profits. Earnings per share was -2.16.
| Revenue | 2.25B |
| Gross Profit | 1.92B |
| Operating Income | -176.88M |
| Net Income | -278.16M |
| EBITDA | -178.85M |
| EBIT | -235.52M |
| Earnings Per Share (EPS) | -2.16 |
Full Income StatementBalance Sheet
The company has 966.43M in cash and 1.3B in
debt, giving a net cash position of -329.62M.
| Cash & Cash Equivalents | 966.43M |
| Total Debt | 1.3B |
| Net Cash | -329.62M |
| Retained Earnings | n/a |
| Total Assets | 4.21B |
| Working Capital | 2.19B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -8.31M
and capital expenditures -34.28M, giving a free cash flow of -42.59M.
| Operating Cash Flow | -8.31M |
| Capital Expenditures | -34.28M |
| Free Cash Flow | -42.59M |
| FCF Per Share | -0.33 |
Full Cash Flow StatementMargins
Gross margin is 85.62%, with operating and profit margins of -7.87% and -12.37%.
| Gross Margin | 85.62% |
| Operating Margin | -7.87% |
| Pretax Margin | -16.79% |
| Profit Margin | -12.37% |
| EBITDA Margin | -7.95% |
| EBIT Margin | -7.87% |
| FCF Margin | -1.89% |
